Measuring What Matters: Beyond BMI

Medical Disclaimer: This content is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Information is based on current medical literature and clinical guidelines but may not apply to your specific situation. Individual responses vary based on personal medical history and concurrent conditions. Always consult qualified healthcare providers for medical decisions. Never delay seeking medical care based on content you’ve read. If experiencing a medical emergency, seek immediate medical attention.

These articles provide education to enhance your healthcare partnership. All treatment decisions should involve your healthcare team. Use this knowledge to have informed discussions, not replace medical care.

In Brief

No single number captures cardiometabolic health, because each measurement answers a different question. This article organizes the measurements that matter around four practical questions — how much fat there is and where it sits, what the body is doing with it, what the body can do, and whether the trajectory is improving. It explains which numbers you can follow yourself, which need laboratory testing, what a meaningful change looks like, and why a trend usually tells you more than a single reading. The goal is not to chase any one figure, but to read a small set of measures together, over time, with a clinician.

Why the Scale Cannot Tell the Whole Story

Consider two people. One loses only a few pounds over several months, yet their waist shrinks, their blood pressure falls, their triglycerides and blood sugar improve, and they can climb stairs that used to leave them winded. Another has a “normal” body mass index but carries fat around the abdomen, has blood pressure creeping upward, blood sugar drifting into the prediabetes range, and little exercise capacity. The scale might make the first person’s progress look disappointing, while BMI might make the second person’s risk look reassuring. Both impressions would miss much of what matters.

The answer to BMI’s limitations is not to replace it with a single better number. It is to stop expecting one number to answer several different biological questions. Weight and BMI are useful pieces of information, but they are incomplete, and taken alone they can point in the wrong direction. The measurements that follow fill the gap. None is a verdict on its own; each answers a specific question, and the value comes from reading them together.

This is the third of eleven articles. Articles 1 and 2 established what fat does and why its location matters; this one turns those ideas into the specific measures the rest of the series refers back to.

BMI: A Screening Tool, Not the Whole Diagnosis

Body mass index — weight divided by height squared — is genuinely useful. It is quick, cheap, and at the population level it tracks health risk well enough to be a reasonable first screen. The difficulty is not that BMI is worthless; it is that BMI is often asked to do a job it cannot do. It does not measure body fat directly, and it cannot show where fat is stored. Two people with the same BMI can have substantially different body composition and substantially different cardiometabolic risk — which is exactly why Article 2 focused on fat distribution rather than total weight.

Recent thinking has moved in this direction. In January 2025, a Lancet Diabetes & Endocrinology Commission — endorsed by more than 75 medical organizations — proposed that BMI be treated as a screening tool rather than a stand-alone diagnosis, and that excess adiposity be confirmed with at least one additional measure of body size, such as waist circumference or waist-to-height ratio.¹ The Commission also drew a distinction between preclinical obesity — excess adiposity that has not yet produced organ dysfunction — and clinical obesity, in which excess adiposity is already impairing the function of the body.¹ The framework is influential but not yet universally adopted; its central principle is that BMI should be interpreted alongside adiposity, fat distribution, and evidence of health impairment.¹

The table makes the point concrete. Both people have a BMI of 29. Their cardiometabolic profiles are not alike.

The Same BMI, Two Different Profiles (Illustrative teaching example. The values are hypothetical and do not necessarily occur together.)

BMI sees two similar people. The cardiometabolic profile sees two different ones. The rest of this article is about the measurements that reveal the difference.

The Four Questions a Better Measurement System Should Answer

Rather than walk through a list of tests, it helps to organize measurement around four questions. The first three describe the current picture; the fourth asks whether that picture is changing over time. Each has its own set of measures, and together they cover what a single number cannot.

The sections that follow take the questions in turn.

Question 1 — How Much, and Where?

Weight and its trajectory. A single weight tells you little, but a trend can tell you a good deal. Weight that is stable, gradually rising, falling with intention, or falling without explanation each mean something different — and unintentional weight loss, in particular, is worth discussing with a clinician. Day-to-day fluctuation reflects water, sodium, glycogen, and the contents of the gut far more than fat, so a single reading is noisy; the direction over weeks and months is the signal. Current weight is also just one frame of a longer film: maximum adult weight, the recent direction of change, and a history of repeated large losses and regains add context that today’s number cannot (Article 8 takes up why weight is regained). The scale is not meaningless. It is incomplete — most informative when read as a trajectory and alongside the other measures here.

BMI belongs in this question as a quick screen of size, with the limitations already described.

Waist circumference is a practical way to capture central (abdominal) adiposity, the pattern associated with cardiometabolic risk described in Article 2. It does not directly measure visceral fat, and it cannot separate visceral from subcutaneous fat, but it carries information about cardiometabolic risk that BMI alone misses.² How much it adds on top of blood pressure, glucose, and lipids depends on which of those are already known — but as a simple, low-cost measure that a person can track at home, it earns its place. Technique matters: measure at the midpoint between the lowest rib and the top of the hip bone, with the tape level and held at the end of a normal breath out.³ Different clinical protocols use slightly different anatomical sites, so when following a trend, use the same method and location each time.

Waist-to-height ratio (WHtR) is waist circumference divided by height. Its appeal is simplicity: a widely used screening message is to keep the waist under half of height (a ratio below 0.5), which the UK’s NICE guidance recommends as a practical marker of central adiposity for adults with a BMI under 35.³ This is a useful screening heuristic, not an absolute biological dividing line. NICE also recommends lower BMI thresholds for identifying overweight and obesity risk in several ethnic groups, including South Asian, Chinese, other Asian, Middle Eastern, Black African, and African-Caribbean populations.³

Question 2 — What Is the Body Doing With It?

Excess or dysfunctional adipose tissue can act on the rest of the body through several pathways — insulin resistance, altered lipid metabolism, inflammation, effects on blood-pressure regulation, and fat deposited in organs where it does not normally belong.² Four sets of measures reveal whether those downstream effects are present.

Blood pressure is the force of blood against the artery walls, and it is one of the most important modifiable cardiovascular risk factors.⁴ In the 2025 US guideline, categories are defined as normal below 120/80 mm Hg; elevated at 120–129 systolic and under 80 diastolic; stage 1 hypertension at 130–139 systolic or 80–89 diastolic; and stage 2 at 140/90 or above.⁴ Those are classifications, not a diagnosis from one reading: blood pressure varies through the day and often rises in the clinic, so diagnosis and treatment decisions rest on repeated, properly taken measurements, frequently including readings at home.⁴

Blood sugar comes with defined cut points. A1c reflects average glucose over roughly the preceding three months, while fasting glucose is a single-moment snapshot. Prediabetes is defined as an A1c of 5.7–6.4% or a fasting glucose of 100–125 mg/dL, and diabetes as an A1c of 6.5% or higher or a fasting glucose of 126 mg/dL or higher.⁵ In the absence of unequivocal hyperglycemia, diagnosis generally requires confirmatory testing rather than resting on a single abnormal result.⁵ There is also an important subtlety: glucose can read normal while insulin resistance is already underway. As tissues become less responsive to insulin, the pancreas compensates by producing more of it, which can hold glucose in the normal range for a time; only when that compensation begins to fall short do fasting glucose and A1c rise.⁶ The practical implication is not that everyone should chase a fasting-insulin number — diabetes is diagnosed from glucose and A1c, there is no standardized fasting-insulin threshold used to diagnose insulin resistance in routine care,⁵ and assessment relies instead on the broader picture (waist and adiposity, glucose, triglycerides, HDL-C, blood pressure, and associated conditions). But it is a reason the other measures matter even when the sugar looks reassuring.

The lipid panel reports several numbers that are not interchangeable, and it helps to separate two ideas. Triglycerides and HDL-C often provide clues to the metabolic environment and frequently move with insulin resistance and central adiposity. The numbers that track plaque most directly are the ones that reflect atherogenic particles. LDL-C measures the cholesterol carried within LDL particles. Non-HDL cholesterol captures the cholesterol in the broader set of atherogenic particles, including the triglyceride-rich remnants that LDL-C misses, which is why it is more informative when triglycerides are high. Apolipoprotein B (ApoB) goes a step further and reflects the number of atherogenic particles, since each carries a single ApoB molecule. In people with diabetes, elevated triglycerides, obesity, or other cardiometabolic risk factors, LDL-C may not fully reflect the atherogenic particle burden; non-HDL-C, and in selected situations ApoB, can add information, and current guidance gives ApoB a targeted role in exactly those settings rather than as a universal test.⁹ The Cholesterol series covers lipid targets in depth; the point here is that “cholesterol” is not one number.

Kidney markers belong in this question too. The kidney is part of what the American Heart Association frames as cardiovascular-kidney-metabolic (CKM) health, in which excess or dysfunctional fat, metabolic risk factors, kidney disease, and cardiovascular disease form one connected system.¹⁰ Two measures capture it: the estimated glomerular filtration rate (eGFR), a blood-based estimate of filtering capacity, and the urine albumin-to-creatinine ratio (UACR), where persistent albumin in the urine can signal kidney damage and increased cardiovascular risk.¹⁰ Most people do not self-track these, but they are part of the integrated assessment a framework built on CKM has to include.

Question 3 — What Can the Body Do?

The first two questions describe what is present. This one asks what the body can actually do — and it is where routine care most often falls short.

Activity and fitness are not the same thing. Physical activity is what a person does; cardiorespiratory fitness is the body’s capacity to take in and use oxygen during sustained effort. The two are related but distinct: a person can increase activity before fitness measurably changes, be active yet have limited fitness, or carry good fitness from years of habitual activity. Fitness can also improve well before — or without — a large change on the scale.

Cardiorespiratory fitness (CRF) is one of the strongest predictors of cardiovascular and overall survival, yet it is the measurement most often missing from a check-up. The American Heart Association has argued it should be treated as a clinical vital sign, noting it predicts mortality at least as strongly as smoking, high blood pressure, high cholesterol, and type 2 diabetes.⁷ A 2024 overview of meta-analyses, covering more than 20 million observations, found that each 1-MET higher level of fitness was associated with an 11–17% lower risk of death from any cause, and that people in the highest fitness category had roughly half the mortality risk of those in the lowest.⁸ Two features make this clinically important: the association extends across the fitness range, and cardiorespiratory fitness is modifiable.⁷,⁸

How would you know yours? Fitness can be assessed along a hierarchy. Formal cardiopulmonary exercise testing directly measures peak oxygen uptake and is used for specific clinical indications. Exercise treadmill testing can estimate functional capacity in appropriate settings, and simpler field or walking tests are used in others. Consumer wearables provide estimates useful for following a personal trend but are not equivalent to laboratory testing. You do not need any of this to begin paying attention to function: pick one consistent, repeatable marker suited to your situation — usual walking pace, the time or distance you tolerate on a familiar route, or how many flights of stairs you climb comfortably — and follow it over time. One boundary matters for a cardiovascular audience: new chest discomfort, unusual breathlessness, fainting, or a clear decline in exercise capacity should not be treated as a self-fitness test; they warrant medical evaluation. Strength and everyday function belong in this question as well, particularly for older adults — a point the next section returns to.

When Body-Composition Testing Helps — and Its Limits

Because BMI cannot separate fat from muscle, body-composition testing is sometimes offered to do exactly that. The methods are not interchangeable. DXA scans estimate total and regional body composition — how much fat and lean mass, and roughly where. CT and MRI can go further and characterize specific fat depots, including visceral and ectopic fat, much more directly.² Consumer bioimpedance devices — the sensors in some scales — give only approximate readings: hydration, recent meals, and recent exercise all shift the estimate, and different devices are not interchangeable, so any value is best used, if at all, to follow a trend measured under similar conditions.

For routine cardiometabolic assessment, waist circumference alongside the metabolic measures is generally the more practical approach.² But body composition can be clinically relevant in specific situations: separating high muscle mass from high fat in a very muscular person whose BMI overstates risk, and assessing frailty, aging, or large intentional weight loss.

Why weight loss and better body composition are not always the same thing. This matters most for older adults, and increasingly in the era of highly effective obesity medications. Weight loss typically includes some loss of lean mass as well as fat mass, and how much varies with the person, the method, the pace, and age.¹² With larger or faster losses, and in older adults already vulnerable to age-related muscle decline, preserving muscle and strength becomes part of the goal — which the scale alone cannot show. A large drop in weight accompanied by substantial loss of muscle is not the same result as preferential fat loss with preserved function, even if the scale reports the same number.

Question 4 — Is the Trajectory Improving?

The single most useful habit in cardiometabolic measurement is to follow trends rather than snapshots. A framework built on isolated readings is easily misled by ordinary variation; consistent trends are usually more informative.

It helps to separate three things a change can represent. A biological change means the underlying state has actually shifted. Measurement variation means the state is similar but the number fluctuates — blood pressure of 154/92 after rushing into the clinic and 132/80 after five minutes seated is not biological improvement. Measurement error means the comparison itself is unreliable — a two-pound overnight change is not two pounds of fat, and a one-inch waist difference measured at two different sites may not be real change at all. Different measures also move on different timescales: A1c reflects roughly three months and changes slowly, so repeating it every few weeks is uninformative; triglycerides can vary with recent food intake, alcohol use, and metabolic conditions; fitness can improve before weight does. The operating principle that follows is simple: standardize what you can, repeat what varies, and follow the direction of travel.

Getting clean data depends on consistent technique:

• Weight: similar time of day and conditions.
• Waist: the same anatomical site and technique each time.³
• Blood pressure: a validated device, correct cuff size, proper positioning, and repeated readings.⁴
• Laboratory values: interpreted in clinical context, with fasting status noted where it matters.
• Fitness: compare the same task or test, not unrelated activities.
• Body composition: the same method under similar conditions.

Not every trend is a lifestyle scorecard. An unexpected decline in exercise capacity or strength, a rapidly changing waist, weight shifts confounded by swelling, or unexplained deterioration in lab values can be clinical signals worth medical attention rather than feedback on effort. Exactly how often to track any given number depends on the person and the purpose; because turning this into a personal plan is a different job from understanding the measures, Article 11 covers how to build that plan.

A Cardiometabolic Measurement Dashboard

The aim is not to acquire every test; it is to know which few numbers to follow.

In practice, that sorts into two tiers:

• The basic picture, for most people: weight trend, waist, blood pressure, glucose status when clinically appropriate, a lipid profile, and one everyday measure of function or fitness.²,³,⁴,⁵,⁹
• Additional measures, based on clinical context: ApoB, kidney assessment with eGFR and UACR when indicated, formal fitness testing, or body-composition assessment.⁷,⁹,¹⁰

Which few to choose, and how often to follow them, is the planning question Article 11 is built around.

Reading the Measures Together

The premise of this article is that measures must be read as a set, so it is worth showing how common patterns are interpreted — because progress and strain both tend to show up as combinations, not as one number.

A short illustration ties it together. Take the same hypothetical Person B from earlier, six months on:

Six Months Later (Illustrative; hypothetical values.)

The scale shows just four pounds lost — under 2%, and easy to dismiss. The fuller picture shows a substantially smaller waist, better blood pressure, improved glycemic status, lower triglycerides, and a substantial improvement in walking capacity. The point is not that weight loss is irrelevant; it is that the biological response is larger than the scale alone can describe. One caution on interpretation: a change like this may reflect lifestyle, medication, or both. Measurement tells you what changed; understanding why takes clinical context.

How Risk Calculators Fit In

The measures operate at three levels. What is present now — weight, waist, blood pressure, glucose, lipids, and kidney markers — describes the current state. What is the accumulated risk can be estimated, when appropriate for a person’s age and clinical situation, by a validated tool such as the American Heart Association’s PREVENT equations, which combine several of these inputs to estimate the chance of cardiovascular disease over 10 and 30 years.¹¹ What is changing over time is the trajectory of the underlying measures. A risk estimate summarizes several risk factors at one point in time; it does not replace following the underlying measures themselves, and small short-term shifts in a calculated percentage should not be overinterpreted.

What “Normal” Does — and Does Not — Mean

Laboratory reference intervals, diagnostic thresholds, and treatment targets are three different things. Reference intervals describe how a measure is distributed across a population; diagnostic thresholds define categories such as prediabetes or hypertension; treatment targets depend on the clinical situation. A concrete case makes the distinction clear: an LDL-C value flagged as “within range” on a lab report may still sit above the treatment goal for someone with established atherosclerotic cardiovascular disease, for whom guidelines set a lower target.⁹ Conversely, crossing a diagnostic threshold does not by itself set a treatment plan without the rest of the clinical picture. Cardiovascular risk is often continuous rather than a step that switches on at a cut point, so “within range” is not the same as “no action needed,” and it is not the same risk for everyone. Reading a number as “normal, therefore fine” is one of the more common ways the fuller picture gets missed.

Clinical Bottom Line

No one number captures cardiometabolic health. Organized around four questions — how much and where, what the body is doing with it, what the body can do, and whether the trajectory is improving — a small set of measures gives a far truer picture than weight or BMI alone. The useful habit is not to chase any single figure, but to follow a few relevant measures over time, interpret them together, and judge progress by direction rather than by a single reading — with a clinician, who can decide which measures fit your situation and how often to follow them.

What Comes Next

With the measures in hand, the series turns to what actually moves them. Article 4 covers the foundations — food, movement, sleep, and stress — and how each acts on the adiposity and cardiometabolic risk this article learned to measure.

Key Terms

Body mass index (BMI): Weight divided by height squared; a quick screen of body size that does not measure body fat directly or show where fat is stored.

Preclinical vs clinical obesity: Excess adiposity without organ dysfunction (preclinical) versus excess adiposity already impairing the body’s function (clinical).

Waist circumference: The distance around the abdomen; a simple marker of central (abdominal) fat that captures risk BMI can miss.

Waist-to-height ratio (WHtR): Waist divided by height; a value under 0.5 is a practical screening marker of central adiposity, not an absolute diagnostic line.

Blood pressure: The force of blood against the artery walls; diagnosed from repeated, properly taken readings rather than one measurement.

A1c and fasting glucose: A1c reflects average glucose over about three months; fasting glucose is a single-moment reading. Both identify prediabetes and diabetes.

Insulin resistance: A state in which tissues respond less well to insulin; the pancreas compensates by producing more, which can keep glucose normal for a time.

LDL-C, non-HDL-C, and ApoB: LDL-C is the cholesterol in LDL particles; non-HDL-C captures cholesterol in all atherogenic particles; ApoB reflects the number of atherogenic particles, and can add information in selected settings.

eGFR and UACR: A blood-based estimate of kidney filtering capacity, and a urine test for albumin; the core kidney measures in the cardiovascular-kidney-metabolic picture.

Cardiorespiratory fitness (CRF): The body’s capacity to take in and use oxygen during sustained effort; a strong, independent predictor of survival, and distinct from physical activity.

Body composition: The split between fat and lean mass and, with some methods, the location of fat; measured in detail by DXA, CT, or MRI.

PREVENT equations: An American Heart Association tool that estimates cardiovascular risk over 10 and 30 years when appropriate for the person.

References

1. Rubino F, Cummings DE, Eckel RH, et al. Definition and diagnostic criteria of clinical obesity. Lancet Diabetes Endocrinol. Published online January 14, 2025. https://doi.org/10.1016/S2213-8587(24)00316-4
2. Neeland IJ, Ross R, Després JP, et al; International Atherosclerosis Society; International Chair on Cardiometabolic Risk Working Group on Visceral Obesity. Visceral and ectopic fat, atherosclerosis, and cardiometabolic disease: a position statement. Lancet Diabetes Endocrinol. 2019;7(9):715–725. https://doi.org/10.1016/S2213-8587(19)30084-1
3. National Institute for Health and Care Excellence. Overweight and obesity management. NICE guideline NG246. London: NICE; 2025. https://www.nice.org.uk/guidance/ng246
4. Jones DW, Ferdinand KC, Taler SJ, et al. 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults. Circulation. 2025;152(11):e114–e218. https://doi.org/10.1161/CIR.0000000000001356
5. American Diabetes Association Professional Practice Committee. 2. Diagnosis and Classification of Diabetes: Standards of Care in Diabetes—2025. Diabetes Care. 2025;48(Suppl 1):S27–S49. https://doi.org/10.2337/dc25-S002
6. Petersen MC, Shulman GI. Mechanisms of Insulin Action and Insulin Resistance. Physiol Rev. 2018;98(4):2133–2223. https://doi.org/10.1152/physrev.00063.2017
7. Ross R, Blair SN, Arena R, et al. Importance of Assessing Cardiorespiratory Fitness in Clinical Practice: A Case for Fitness as a Clinical Vital Sign: A Scientific Statement From the American Heart Association. Circulation. 2016;134(24):e653–e699. https://doi.org/10.1161/CIR.0000000000000461
8. Lang JJ, Prince SA, Merucci K, et al. Cardiorespiratory fitness is a strong and consistent predictor of morbidity and mortality among adults: an overview of meta-analyses representing over 20.9 million observations from 199 unique cohort studies. Br J Sports Med. 2024;58(10):556–566. https://doi.org/10.1136/bjsports-2023-107849
9. Blumenthal RS, Morris PB, Gaudino M, et al. 2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia. Circulation. 2026;153:e1154–e1276. https://doi.org/10.1161/CIR.0000000000001423
10. Ndumele CE, Rangaswami J, Chow SL, et al. Cardiovascular-Kidney-Metabolic Health: A Presidential Advisory From the American Heart Association. Circulation. 2023;148(20):1606–1635. https://doi.org/10.1161/CIR.0000000000001184
11. Khan SS, Coresh J, Pencina MJ, et al. Novel Prediction Equations for Absolute Risk Assessment of Total Cardiovascular Disease Incorporating Cardiovascular-Kidney-Metabolic Health: A Scientific Statement From the American Heart Association. Circulation. 2023;148:1982–2004. https://doi.org/10.1161/CIR.0000000000001191
12. Stefanakis K, Kokkorakis M, Mantzoros CS. The impact of weight loss on fat-free mass, muscle, bone and hematopoiesis health: implications for emerging pharmacotherapies aiming at fat reduction and lean mass preservation. Metabolism. 2024;161:156057. https://doi.org/10.1016/j.metabol.2024.156057

HeartBuddi • Your heart. Own it.